31 related articles for article (PubMed ID: 12821344)
1. Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.
Alexandrakis MG; Pappa CA; Kolovou A; Kyriakaki S; Vyzoukaki R; Devetzoglou M; Tsirakis G
Med Oncol; 2014 May; 31(5):953. PubMed ID: 24729186
[TBL] [Abstract][Full Text] [Related]
2. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance.
Zhao H; Zheng L; Li X; Wang L
Sci Rep; 2014 Jan; 4():3866. PubMed ID: 24473454
[TBL] [Abstract][Full Text] [Related]
3. The immunoregulatory mechanisms of carcinoma for its survival and development.
Du C; Wang Y
J Exp Clin Cancer Res; 2011 Jan; 30(1):12. PubMed ID: 21255410
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune escape mechanisms: impact of the neuroendocrine system.
Lang K; Entschladen F; Weidt C; Zaenker KS
Cancer Immunol Immunother; 2006 Jul; 55(7):749-60. PubMed ID: 16435128
[TBL] [Abstract][Full Text] [Related]
5. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.
Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D
J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated FasL gene transfer into human gastric carcinoma.
Zheng SY; Li DC; Zhang ZD; Zhao J; Ge JF
World J Gastroenterol; 2005 Jun; 11(22):3446-50. PubMed ID: 15948252
[TBL] [Abstract][Full Text] [Related]
7. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Ahmad M; Rees RC; Ali SA
Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
[TBL] [Abstract][Full Text] [Related]
8. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.
Chen J; Wang R; Zhang B; Lin X; Wei J; Jia Y; Yin Y; Ye S; Zhu T; Chen G; Yuan Y; Lu W; Li K
Am J Obstet Gynecol; 2016 Oct; 215(4):460.e1-460.e13. PubMed ID: 27133009
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
Lax SF; Tamussino KF; Lang PF
Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression.
Kase H; Aoki Y; Tanaka K
Gynecol Oncol; 2003 Jul; 90(1):70-4. PubMed ID: 12821344
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
[TBL] [Abstract][Full Text] [Related]
12. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
[TBL] [Abstract][Full Text] [Related]
13. Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer.
Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
Gynecol Oncol; 2005 Jun; 97(3):772-9. PubMed ID: 15943986
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fas ligand is an early event in colorectal carcinogenesis.
Shimoyama M; Kanda T; Liu L; Koyama Y; Suda T; Sakai Y; Hatakeyama K
J Surg Oncol; 2001 Jan; 76(1):63-8; discussion 69. PubMed ID: 11223827
[TBL] [Abstract][Full Text] [Related]
15. Research on expression and importance of p53, p16 and VEGF-C in cervical cancer.
Cai S; Han K
J Gynecol Obstet Biol Reprod (Paris); 2015 Sep; 44(7):639-45. PubMed ID: 25443468
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
